Study of Rifampicin in Multiple System Atrophy
Stopped DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.
Conditions
Interventions
- DRUG: Rifampicin
- DRUG: placebo
Sponsor
Phillip Low
Collaborators
- [object Object]
- [object Object]
- [object Object]